IP Library Granted Patent US 9,238,017
Granted Patent B2
US 9,238,017 · App. 13/197,581 · Granted Jan 19, 2016

Compositions with reduced hepatotoxicity

Inventor: Joel E. Bernstein (Deerfield, IL)
Assignee: Winston Laboratories, Inc.
A61K31/198A61K9/0019A61K31/167A61K47/18A61K47/183
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,238,017
App. No.
13/197,581
Granted
Jan 19, 2016
Kind
B2
Abstract

Pharmaceutical compositions of hepatotoxic compounds are provided in which the hepatotoxicity of the compounds is mitigated by including quantities of nicotinamide and methionine in the composition. Folic acid also can be included to further mitigate the hepatotoxic effects. The hepatotoxic compounds can include acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanozole, divalproex sodium, and valproic acid.

Claims (10)

1. A method of mitigating the hepatotoxicity of a hepatotoxic compound, the method comprising:

formulating a composition of the hepatotoxic compound by combining a quantity of the hepatotoxic compound with a quantity of nicotinamide, a quantity of methionine, and a quantity of folic acid into a single individual dosage form selected from the group consisting of a capsule, a tablet or an oral solution,

and further administering the individual dosage form containing the hepatotoxic compound, nicotinamide, folic acid, and methionine to a patient in need of the hepatotoxic compound,

wherein the hepatotoxic compound is selected from the group consisting of acetaminophen, atorvastatin, simvastatin, niacin, fluconazole, divalproex sodium, and valproic acid.

2. The method of claim 1 wherein said composition is formulated such that for each dose of the hepatotoxic compound in the composition, the nicotinamide is present in the amount of 5-500 mg, and the methionine is present in the amount of 25-500 mg.

3. The method of claim 2 wherein said nicotinamide is present in the amount of 25-200 mg per dose of the hepatotoxic compound.

4. The method of claim 2 wherein said methionine is present in the amount of 10-100 mg per dose of the hepatotoxic compound.

5. The method of claim 1 wherein said folic acid is present in the amount of 50 mcg-5 mg per dose of the hepatotoxic compound.

6. The method of claim 5 wherein said folic acid is present in the amount of 500 mcg-1 mg per dose of the hepatotoxic compound.

7. The method of claim 1 , wherein said acetaminophen is present in the amount of 80 mg-1000 mg per dose.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2023
From: ELORAC, INC.
To: ELORAC CREDITORS TRUST
Reel/Frame 065074/0625 →
MERGER AND CHANGE OF NAME Recorded Jan 25, 2023
From: GIDEON PHARMACEUTICALS, INC.; ELORAC, INC.
To: ELORAC, INC.
Reel/Frame 062486/0613 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 24, 2023
From: WINSTON LABORATORIES, INC.
To: GIDEON PHARMACEUTICALS, INC.
Reel/Frame 062464/0870 →
Continuity (2)
Division 10813760 · Mar 31, 2004
Related Publication 20110288099A1 · Nov 24, 2011